Throughout TAP's history, its efforts have been focused on developing and bringing innovative treatments to the people who need them. LUPRON® INJECTION (leuprolide acetate), TAP's first product, was the first new hormonal therapy for the palliative treatment of advanced prostate cancer in 40 years. Prevacid® (lansoprazole), a proton pump inhibitor (PPI), quickly became one of the most widely prescribed therapies for acid-related disease in North America. And the focus on innovation continues as the people of TAP work to improve patient convenience with new dosing and packaging advancements, research new indications for existing products, and develop new products in the pipeline.

2004
TAP names new management team of Alan MacKenzie, President and Glenn Warner, Executive Vice President.

TAP submits New Drug Application(NDA) to the U.S. Food and Drug Administration(FDA) for febuxostat for the management of hyperuricemia in chronic gout.

The U.S. FDA approves several new options for patients using Prevacid:

• Labeling for use of Prevacid in adolescents aged 12 to 17.

• New dosing options for Prevacid®(lansoprazole) SoluTab^TM Orally Disintegrating Tablets.

• Prevacid I.V.(lansoprazole) for Injection was approved for use in the treatment of erosive esophagitis in hospitalized patients.

2003
TAP introduces Prevacid® NapraPAC^TM (lansoprazole delayed release capsules and naproxen tablet kit) a first of its kind combination package containing two widely used medications in one prescription.

TAP introduces Lupron Depot® (leuprolide acetate for depot suspension) with LuproLoc^TM, making Lupron Depot the first product in its class to offer a needlestick safety device on its prefilled syringes.

TAP ends agreement with Unimed/Solvay Pharmaceuticals to co-promote Androgel®
1% (testosterone gel).

TAP returns rights to Spectracef® (cefditoren pivoxil) to partner Meiji Seika Kaisha, Ltd. of Japan.

2002
Prevacid becomes available through Together RxTM, an innovative program from members of the pharmaceutical industry to provide prescription medication discounts for seniors without prescription drug insurance coverage.

2001
TAP enters co-promotion agreement with Unimed/Solvay Pharmaceuticals for AndroGel 1% (testosterone gel).

TAP enters collaborative research agreement with Ligand Pharmaceuticals.

Spectracef approved by FDA.

Lupron Depot add-back therapy approved by FDA.

Prevacid is the first PPI approved in a packet for oral suspension.

2000
Prevacid becomes the first PPI approved by the FDA for the treatment and risk reduction of recurrence of NSAID-associated (nonsteroidal anti-inflammatory drug) gastric ulcers in chronic NSAID users.

TAP enters a long-term research collaboration with IPF PharmaCeuticals GmbH.

1999
Prevpac® (lansoprazole/amoxicillin/clarithromycin) 10-day triple therapy approved for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

Prevacid approved for new administration options, including sprinkling on cottage cheese, yogurt or Ensure® pudding or strained pears, as well as mixing with orange juice and tomato juice.

NDA filed with FDA for Spectracef.

1998
Prevacid approved for short-term treatment of symptomatic gastroesophageal reflux disease and, in combination with clarithromycin and amoxicillin, for 10-day therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

1997
Prevacid approved for short-term treatment of active benign gastric ulcers and maintenance of healed duodenal ulcer.

Prevacid in combination with clarithromycin and amoxicillin approved for 14-day therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

Prevpac blister packaging approved for 14-day triple therapy for eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.

Lupron Depot-3 Month 11.25 mg approved for treatment of endometriosis and, in combination with iron, for presurgical treatment of anemia caused by uterine fibroids.

Lupron Depot-4 Month 30 mg approved for palliative treatment of advanced prostate cancer.

1996
Prevacid approved for long-term maintenance of healed erosive esophagitis.

The Prevacid launch becomes one of the most successful in pharmaceutical history.

Pharmacy Solutions introduced.

1995
Prevacid approved by FDA for short-term treatment of erosive esophagitis, active duodenal ulcers and pathological hypersecretory conditions.

Lupron Depot 3.75 approved, in combination with iron, for presurgical treatment of anemia caused by uterine fibroids.

Lupron Depot-3 Month 22.5 mg approved for palliative treatment of advanced prostate cancer.

CaPSURE^TM introduced.

1994
TAPCare introduced.

1993
Lupron Depot-PED® (leuprolide acetate for depot suspension) approved for treatment of central precocious puberty.

1990
Lupron Depot 3.75 mg approved for management of endometriosis.

1989
Lupron Depot 7.5 mg approved for palliative treatment of advanced prostate cancer.

1985
LUPRON® INJECTION (leuprolide acetate) approved by FDA for palliative treatment of advanced prostate cancer, the first new hormonal treatment for prostate cancer in 40 years.

1977
Takeda Chemical Industries, Ltd. and Abbott form a joint research partnership, Takeda-Abbott Products (TAP).

For further information regarding these products, including adverse events, please consult prevacid.com, lupron.com, and complete prescribing information.

Androgel®, Ensure® and Spectracef® are not registered trademarks of TAP Pharmaceutical Products Inc.

Spectracef® is licensed to Purdue Pharmaceutical Products L.P. by Meiji Seika Kaisha, Ltd.